button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -- 0.40 [0.20; 0.79], 1 RCT, I2=0%
unassessable degree of certainty
versus placebo
nivolumab plus ipilimumab vs. placebo 1 -- 0.23 [0.12; 0.45], 1 RCT, I2=0% conclusive
unassessable degree of certainty

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 2 0.58 [0.46; 0.74], 2 RCTs, I2=0% conclusive
high degree of certainty		 0.41 [0.32; 0.53], 2 RCTs, I2=0% conclusive
high degree of certainty		-
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 0.65 [0.53; 0.80], 1 RCT, I2=0%
unassessable degree of certainty		 0.74 [0.60; 0.92], 1 RCT, I2=0%
unassessable degree of certainty		-

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 1.44 [0.46; 4.49], 1 RCT, I2=0%
inconclusive result		 0.38 [0.15; 0.98], 1 RCT, I2=0%
unassessable degree of certainty		-

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 - 0.40 [0.23; 0.69], 1 RCT, I2=0% conclusive
unassessable degree of certainty		-

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons